Should I buy or sell Design Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks .

What is Design Therapeutics' stock price target for 2024?

7 analysts have issued 12 month price objectives for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 44.4% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts .

How have DSGN shares performed in 2024?

Design Therapeutics' stock was trading at $2.65 at the start of the year. Since then, DSGN shares have increased by 43.8% and is now trading at $3.81. View the best growth stocks for 2024 here .

When is Design Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our DSGN earnings forecast .

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) posted its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.11.

What ETF holds Design Therapeutics' stock?

iShares Neuroscience and Healthcare ETF holds 4,013 shares of DSGN stock, representing 0.64% of its portfolio.

When did Design Therapeutics IPO?

Design Therapeutics (DSGN) raised $228 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DSGN

Design Therapeutics (DSGN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free DSGN Stock Alerts

$3.75

+0.01 (+0.27%)

(As of 02:27 PM ET)

Compare

Today's Range: $3.68
▼
$3.90
50-Day Range: $2.27
▼
$4.03
52-Week Range: $1.94
▼
$8.47

Volume: 238,695 shs
Average Volume: 262,853 shs
Market Capitalization: $211.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Get Design Therapeutics alerts:

Design Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 44.4% Upside
$5.50 Price Target
Short Interest: Bearish
6.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.67
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$99,750 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.25) to ($1.39) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

497th out of 918 stocks

Pharmaceutical Preparations Industry

226th out of 423 stocks

3.0

Analyst's Opinion

Consensus Rating
Design Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Design Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.75% of the float of Design Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Design Therapeutics has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Design Therapeutics has recently increased by 4.21%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Design Therapeutics does not currently pay a dividend.
Dividend Growth
Design Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DSGN.

3.7

News and Social Media Coverage

News Sentiment
Design Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Design Therapeutics this week, compared to 1 article on an average week.
Search Interest
3 people have searched for DSGN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
6 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Design Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,750.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
27.80% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Design Therapeutics are expected to decrease in the coming year, from ($1.25) to ($1.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Design Therapeutics is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Design Therapeutics is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Design Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Design Therapeutics Stock (NASDAQ:DSGN)

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

DSGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DSGN Stock News Headlines

March 26, 2024 | insidertrades.com

Design Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid Purchases 9,156 Shares

March 26, 2024 | insidertrades.com

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in Stock

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 14, 2024 | americanbankingnews.com

Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Hold" from Analysts

March 27, 2024 | finance.yahoo.com

Independent Director of Design Therapeutics Picks Up 88% More Stock

March 26, 2024 | msn.com

Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

March 21, 2024 | markets.businessinsider.com

RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)

March 21, 2024 | markets.businessinsider.com

Hold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program Updates

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 20, 2024 | stockhouse.com

Design Therapeutics Outlines Progress Across GeneTAC(TM) Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

March 19, 2024 | investorplace.com

DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023

March 19, 2024 | finance.yahoo.com

Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress

March 19, 2024 | globenewswire.com

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

March 18, 2024 | investing.com

Design Therapeutics Inc (DSGN)

March 18, 2024 | benzinga.com

Earnings Preview For Design Therapeutics

March 15, 2024 | finance.yahoo.com

DSGN Jul 2024 2.500 put

March 15, 2024 | finance.yahoo.com

DSGN Apr 2024 7.500 put

March 12, 2024 | globenewswire.com

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

February 9, 2024 | benzinga.com

SR ONE CAPITAL PARTNERS I, LP's Net Worth

December 18, 2023 | finance.yahoo.com

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know

December 7, 2023 | morningstar.com

Design Therapeutics Inc DSGN

November 25, 2023 | finance.yahoo.com

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

November 16, 2023 | markets.businessinsider.com

Hold Rating on Design Therapeutics Amid Mixed Efficacy Data, Strategic Realignment and Financial Uncertainties

November 14, 2023 | finance.yahoo.com

Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update

November 13, 2023 | finance.yahoo.com

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

September 8, 2023 | fool.com

Design Therapeutics (NASDAQ: DSGN)

September 7, 2023 | benzinga.com

Director At This Health Care Company Buys $14.00M of Stock

See More Headlines

Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DSGN
CUSIP: N/A
CIK: 1807120
Web: www.designtx.com
Phone: 858-293-4900
Fax: N/A
Employees: 58
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $6.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +44.4%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-66,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -22.82%
Return on Assets: -21.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 29.58
Quick Ratio: 29.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.96 per share
Price / Book: 0.77

Miscellaneous

Outstanding Shares: 56,490,000
Free Float: 40,789,000
Market Cap: $215.23 million
Optionable: Optionable
Beta: 1.82

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Pratik Shah Ph.D. (Age 54)
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Comp: $638.46k
Dr. Sean Jeffries Ph.D. (Age 44)
Chief Operating Officer
Comp: $572.21k
Dr. Aseem Z. Ansari Ph.D.
Co-Founder & Scientific Advisor
Ms. Julie D. Burgess CPA
Chief Accounting Officer
Dr. Jae B. Kim FACC (Age 54)
M.D., Chief Medical Officer
Ms. Dawn Giangiulio
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DSGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Design Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares.
View DSGN analyst ratings or view top-rated stocks.
What is Design Therapeutics' stock price target for 2024?: 7 analysts have issued 12 month price objectives for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 44.4% from the stock's current price.
View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts.
How have DSGN shares performed in 2024?: Design Therapeutics' stock was trading at $2.65 at the start of the year. Since then, DSGN shares have increased by 43.8% and is now trading at $3.81.
View the best growth stocks for 2024 here.
When is Design Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our DSGN earnings forecast.

How were Design Therapeutics' earnings last quarter?: Design Therapeutics, Inc. (NASDAQ:DSGN) posted its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.11.
What ETF holds Design Therapeutics' stock?: iShares Neuroscience and Healthcare ETF holds 4,013 shares of DSGN stock, representing 0.64% of its portfolio.
When did Design Therapeutics IPO?: Design Therapeutics (DSGN) raised $228 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.
How do I buy shares of Design Therapeutics?: Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DSGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Design Therapeutics (DSGN) Stock Price, News & Analysis

Design Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Design Therapeutics Stock (NASDAQ:DSGN)

DSGN Stock Price History

DSGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DSGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™